Foundayo

2 articles

A symbolic bridge representing Medicare's temporary copay program for obesity drugs, connecting patients to vital medications.

Medicare's temporary $50 copay for obesity drugs like Zepbound

Starting July 1, 2026, eligible Medicare Part D beneficiaries will access branded obesity drugs like Zepbound for a $50 monthly copay, an unprecedented expansion of coverage set to expire just 18 mont

Dr. Evelyn Reed·June 8, 2026

Scientists analyzing data in a high-tech lab, focusing on potential risks of the new obesity drug Foundayo, under FDA scrutiny.

Computational Science & Software

FDA Requests Additional Safety Data for Lilly's Foundayo Obesity Drug

The FDA has requested Eli Lilly conduct additional long-term safety studies for its newly approved oral obesity drug Foundayo, specifically flagging risks like heart attack, stroke, and liver injury.

Yasmin Haddad·June 7, 2026